摘要
目的观察尼莫地平对糖尿病认知功能障碍患者认知功能的影响。方法将70例糖尿病认知功能障碍患者随机分为尼莫地平治疗组(35例,尼莫地平片口服30mg,每日3次);石杉碱甲对照组(35例,石杉碱甲片口服100μg,每日3次)。应用简易精神状态检查量表评定两组患者治疗前后认知功能状况,并进行治疗前后P300检查。结果治疗前两组简易精神状态检查量表评分、P300的潜伏期及波幅差异无显著性(P>0.05)。治疗30、60d时,两组简易精神状态检查量表评分显著提高(尼莫地平组P<0.01,石杉碱甲组P<0.05),P300潜伏期均有缩短,波幅均有提高(两组P<0.01);治疗后60d时认知功能改善尼莫地平组明显优于石杉碱甲组(总有效率分别为83%、57%)(P<0.05)。两组治疗期间无严重不良反应。结论尼莫地平片能够改善糖尿病认知功能障碍患者的认知功能比石杉碱甲组更有效,这可能与尼莫地平能改善脑微循环有关。
Objective To explore the effect of Nimodipine on the cognition impairment of diabetes. Methods 70 cases with cognition impairments resulting from diabetes were randomly divided into Nimodipine group and Huperzine A group. Every patient of Nimodipine group takes 30mg of nimodipine three times a day, and every patient of Huperzine A group takes 100 g of huperzine A,three times a day. Mini mental status scale were used to evaluate the cognition function of two groups before and after treatment. P300 were also conducted at the same time. Results Before treatment, there was no difference between mini mental status scale scores, latency period of P300 and wave amplitude of P300 of two groups. At the time of 30 days and 60 days after treatment,the mini mental status scale scores of both groups were improved significantly（ nimodipine group P 〈 0.01, Huperzine A group,P 〈 0.05 ）. Latency period of P300 of two groups were shortened significantly,wave amplitude of P300 were improved significantly （P 〈0.05）. At the time of 60 days after the treatment, the improvement of cognition of nimodipine group were better than huperzine A group （total effective rate was 71.2% ,63.4% respectively ） （P 〈0.05）. There was no serious adverse reaction in both groups. Conclusion Nimodipine can improve the cognition function of diabetes, and its effect is better than that of huperzine A, The reason may be that nimodipine can improve the microcireulation of brain.
出处
《医学综述》
2008年第16期2539-2541,共3页
Medical Recapitulate
